文献速递骨软组织肉瘤与黑色素瘤

BEMPEG联合纳武利尤单抗一线治疗转移性黑色素瘤

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
PubMed 文献 · J Clin Oncol · 2021-07-13

PIVOT-02研究II期队列评估BEMPEG联合纳武利尤单抗一线治疗41例初治III/IV期黑色素瘤患者,38例可评估疗效。中位随访29.0个月,客观缓解率52.6%,完全缓解率34.2%,中位无进展生存期30.9个月,24个月总生存率77.0%。联合方案耐受性良好,3/4级治疗相关不良事件发生率17.1%。

要点

  • BEMPEG联合纳武利尤单抗一线治疗转移性黑色素瘤客观缓解率52.6%,完全缓解率34.2%。
  • 中位无进展生存期30.9个月,24个月总生存率77.0%。
  • 3/4级治疗相关不良事件发生率17.1%,免疫介导不良事件4.9%。

核心结论

  • BEMPEG联合纳武利尤单抗在初治转移性黑色素瘤中耐受性良好,3/4级治疗相关及免疫介导不良事件发生率相对较低,并显示出令人鼓舞的抗肿瘤活性,包括延长的中位无进展生存期。

研究设计与样本

  • 国际、单臂PIVOT-02研究II期队列,共纳入41例既往未治疗的III/IV期黑色素瘤患者,接受BEMPEG 0.006 mg/kg联合纳武利尤单抗360 mg每3周一次,最长治疗2年,其中38例可评估疗效。

主要发现

  • 中位随访29.0个月时,客观缓解率为52.6%(20/38),完全缓解率为34.2%(13/38)。
  • 可评估疗效人群中,靶病灶大小较基线中位变化为-78.5%,47.4%(18/38)患者靶病灶完全消退。
  • 中位无进展生存期为30.9个月(95% CI,5.3至不可估计),中位总生存期未达到,24个月总生存率为77.0%(95% CI,60.4至87.3)。
  • 3级和4级治疗相关不良事件发生率分别为17.1%(7/41)和4.9%(2/41),免疫介导不良事件发生率分别为17.1%(7/41)和4.9%(2/41)。
  • 治疗后血液中CD8+和CD4+ T细胞的多功能反应增强,早期治疗中血液生物标志物(CD8+多功能强度差和嗜酸性粒细胞)与治疗反应相关。

临床怎么用

  • 对于初治转移性黑色素瘤患者,BEMPEG联合纳武利尤单抗可作为具有较高缓解深度和持久无进展生存潜力的免疫联合治疗选择。
  • 治疗期间可关注早期血液生物标志物(如CD8+多功能强度差和嗜酸性粒细胞)的动态变化,辅助预判影像学反应。

局限性

  • 本研究为单臂II期队列,样本量较小(41例),缺乏随机对照,结论需进一步随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Therapies that produce deep and durable responses in patients with metastatic melanoma are needed. This phase II cohort from the international, single-arm PIVOT-02 study evaluated the CD122-preferential interleukin-2 pathway agonist bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in first-line metastatic melanoma. METHODS: A total of 41 previously untreated patients with stage III/IV melanoma received BEMPEG 0.006 mg/kg plus NIVO 360 mg once every 3 weeks for ≤ 2 years; 38 were efficacy-evaluable (≥ 1 postbaseline scan). Primary end points were safety and objective response rate (blinded independent central review); other end points included progression-free survival, overall survival (OS), and exploratory biomarkers. RESULTS: At 29.0 months' median follow-up, the objective response rate was 52.6% (20 of 38 patients), and the complete response rate was 34.2% (13 of 38 patients). Median change in size of target lesions from baseline was -78.5% (response-evaluable population); 47.4% (18 of 38 patients) experienced complete clearance of target lesions. Median progression-free survival was 30.9 months (95% CI, 5.3 to not estimable). Median OS was not reached; the 24-month OS rate was 77.0% (95% CI, 60.4 to 87.3). Grade 3 and 4 treatment-related and immune-mediated adverse events occurred in 17.1% (7 of 41) and 4.9% (2 of 41) of patients, respectively. Increased polyfunctional responses in CD8+ and CD4+ T cells were seen in blood after treatment, driven by cytokines with effector functions. Early on-treatment blood biomarkers (CD8+ polyfunctional strength difference and eosinophils) correlated with treatment response. CONCLUSION: BEMPEG in combination with NIVO was tolerated, with relatively low rates of grade 3 and 4 treatment-related and immune-mediated adverse events. The combination had encouraging antitumor activity in first-line metastatic melanoma, including an extended median progression-free survival. Exploratory analyses associated noninvasive, on-treatment biomarkers with response, before radiologic evidence was observed.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Diab A, Tykodi SS, Daniels GA, et al. Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. J Clin Oncol. 2021. PMID: 34255535. doi:10.1200/JCO.21.00675

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。